Cargando…
Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptid...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931592/ https://www.ncbi.nlm.nih.gov/pubmed/17594508 http://dx.doi.org/10.1186/1471-2210-7-8 |
_version_ | 1782134284558008320 |
---|---|
author | Yoshimori, Atsushi Sakai, Junichi Sunaga, Satoshi Kobayashi, Takanobu Takahashi, Satoshi Okita, Naoyuki Takasawa, Ryoko Tanuma, Sei-ichi |
author_facet | Yoshimori, Atsushi Sakai, Junichi Sunaga, Satoshi Kobayashi, Takanobu Takahashi, Satoshi Okita, Naoyuki Takasawa, Ryoko Tanuma, Sei-ichi |
author_sort | Yoshimori, Atsushi |
collection | PubMed |
description | BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies. RESULTS: Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with K(i)(app )values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar K(i)(app )values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S(3 )subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S(2 )subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3. CONCLUSION: On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases. |
format | Text |
id | pubmed-1931592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19315922007-07-25 Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO Yoshimori, Atsushi Sakai, Junichi Sunaga, Satoshi Kobayashi, Takanobu Takahashi, Satoshi Okita, Naoyuki Takasawa, Ryoko Tanuma, Sei-ichi BMC Pharmacol Research Article BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies. RESULTS: Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with K(i)(app )values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar K(i)(app )values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S(3 )subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S(2 )subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3. CONCLUSION: On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases. BioMed Central 2007-06-27 /pmc/articles/PMC1931592/ /pubmed/17594508 http://dx.doi.org/10.1186/1471-2210-7-8 Text en Copyright © 2007 Yoshimori et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yoshimori, Atsushi Sakai, Junichi Sunaga, Satoshi Kobayashi, Takanobu Takahashi, Satoshi Okita, Naoyuki Takasawa, Ryoko Tanuma, Sei-ichi Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title | Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title_full | Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title_fullStr | Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title_full_unstemmed | Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title_short | Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO |
title_sort | structural and functional definition of the specificity of a novel caspase-3 inhibitor, ac-dnld-cho |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931592/ https://www.ncbi.nlm.nih.gov/pubmed/17594508 http://dx.doi.org/10.1186/1471-2210-7-8 |
work_keys_str_mv | AT yoshimoriatsushi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT sakaijunichi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT sunagasatoshi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT kobayashitakanobu structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT takahashisatoshi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT okitanaoyuki structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT takasawaryoko structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho AT tanumaseiichi structuralandfunctionaldefinitionofthespecificityofanovelcaspase3inhibitoracdnldcho |